Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. Recently, a subset of these same mutations of ACVR1 have b...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Mohedas, A, Wang, Y, Sanvitale, C, Canning, P, Choi, S, Xing, X, Bullock, A, Cuny, G, Yu, P
Materialtyp: Journal article
Språk:English
Publicerad: 2014

Liknande verk

Liknande verk